Abstract
AA-amyloidosis in the setting of chronic visceral leishmaniasis (VL) has been reported in animal models but documentation in humans is unavailable. Here, we report on a Portuguese man who in 1996 was diagnosed with both human immunodeficiency virus (HIV)-infection and VL. Antiretroviral treatment led to sustained suppression of HIV viremia but CD4+ lymphocytes rose from 8 to only 160 cells/mL. Several courses of antimony treatment did not prevent VL relapses. Renal failure developed in 2006 and renal biopsy revealed AA-amyloidosis. The patient had cryoglobulinemia and serum immune complexes containing antibodies directed against seven leishmanial antigens. Antimony plus amphotericin B, followed by oral miltefosine resulted in a sustained VL treatment response with elimination of circulating Leishmania infantum DNA and CD4+ recovery. The concomitant reduction of serum AA levels and disappearance of circulating leishmanial immune complexes suggests that prolonged VL may lead to AA-amyloidosis in immunocompromised humans. Copyright © 2009 by The American Society of Tropical Medicine and Hygiene.
Cite
CITATION STYLE
De Vallière, S., Mary, C., Joneberg, J. E., Rotman, S., Bullani, R., Greub, G., … Tarr, P. E. (2009). Case report: AA-amyloidosis caused by visceral leishmaniasis in a human immunodeficiency virus-infected patient. American Journal of Tropical Medicine and Hygiene, 81(2), 209–212. https://doi.org/10.4269/ajtmh.2009.81.209
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.